Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study

Neurology 2024 May;102(10):e209349.  doi: 10.1212/WNL.0000000000209349. Epub 2024 Apr 26. Uwe Reuter, Peter J Goadsby, Michel D Ferrari, Gabriel Paiva Da Silva Lima, Subhayan Mondal, Jawed Kalim, Fatima Hasan, Shihua Wen, Michal Arkuszewski, Shaloo Pandhi, Tracy Stites, Michel Lanteri-Minet    Abstract Background and objectives: The LIBERTY study assessed the efficacy and safety of erenumab

“Status trigeminal neuralgia”: Analysis of 39 cases and proposal for diagnostic criteria

Revue Neurologique (Paris) 2024 May 23:S0035-3787(24)00523-X. doi: 10.1016/j.neurol.2024.03.014. Online ahead of print. Z Poullet, S Redon, R Gravier-Dumonceau, A Donnet Abstract Objective: The aim of this descriptive study was to propose diagnostic criteria for acute exacerbation of trigeminal neuralgia (TN) based on the